z-logo
Premium
Effects of water deprivation for 72 hours on the pharmacokinetics of DA‐7867, a new oxazolidinone, in rats
Author(s) -
Bae Soo K.,
Kim Yu C.,
Lee Jae K.,
Kwon Jong W.,
Yoo Moohi,
Lee Inchul,
Lee Myung G.
Publication year - 2006
Publication title -
biopharmaceutics and drug disposition
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.419
H-Index - 58
eISSN - 1099-081X
pISSN - 0142-2782
DOI - 10.1002/bdd.496
Subject(s) - dehydration , pharmacokinetics , chemistry , oral administration , gastrointestinal tract , urine , medicine , endocrinology , pharmacology , biochemistry
The pharmacokinetic parameters of DA‐7867 were compared after intravenous and oral administration at a dose of 10 mg/kg in control rats and in rats with water deprivation for 72 h (rat model of dehydration). After intravenous administration in the rat model of dehydration, the Cl nr (0.654 versus 0.992 ml/min/kg) and Cl r (0.0273 versus 0.0784 ml/min/kg) values were significantly slower than in the controls. The slower Cl nr could be due mainly to a significantly smaller total amount of unchanged DA‐7867 recovered from the gastrointestinal tract at 24 h ( GI 24 h : 5.16% versus 9.21% of intravenous dose) due to impaired liver function in the rat model of dehydration. The slower Cl r could be due mainly to a significantly smaller 24 h urinary excretion of unchanged drug ( Ae 0–24 h : 4.41% versus 7.75% of intravenous dose) due to urine flow rate‐dependent Cl r of DA‐7867 in the rat model of dehydration. Hence, the Cl was significantly slower in the rat model of dehydration (0.677 versus 1.07 ml/min/kg). After intravenous administration in the rat model of dehydration, the V ss of DA‐7867 was significantly smaller than in the controls (396 versus 506 ml/kg) due mainly to significantly smaller free (unbound to plasma proteins) fractions of DA‐7867 in plasma (6.90% versus 29.2%) in the rat model of dehydration. After oral administration in the rat model of dehydration, the AUC was significantly greater than that in controls (10800 versus 7060 µg min/ml) due mainly to a significantly smaller Ae 0–24 h than in controls (3.50% and 6.17% of oral dose). Copyright © 2006 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom